In breast cancer, GATA3 mutations have been associated with a favorable prognosis and the response to neoadjuvant aromatase inhibitor treatment. Therefore, we investigated whether GATA3 mutations predict the outcome of tamoxifen treatment in the advanced setting. In a retrospective study consisting of 235 hormone-naive patients with ER-positive breast cancer who received tamoxifen as first-line treatment for recurrent disease, GATA3 mutations (in 14.0% of patients) did not significantly associate with either the overall response rate (ORR) or with the length of progression-free survival (PFS) after the start of tamoxifen therapy. Interestingly, among 148 patients for whom both mutation and mRNA expression data were available, GATA3 mutations associated with an increased expression of GATA3. However, only 23.7% of GATA3 high tumors had a mutation. Evaluation of the clinical significance of GATA3 mRNA revealed that it was associated with prolonged PFS, but not with the ORR, also in multivariate analysis. Thus, GATA3 mRNA expression, but not GATA3 mutation, is an independent predictor of prolonged PFS in ER-positive breast cancer patients who received first-line tamoxifen for recurrent disease. Besides GATA3 mutation, other mechanisms must exist that underlie increased GATA3 levels.
Introduction
Breast cancer is one of the most frequently diagnosed cancers in Western women. About 70% of all diagnosed breast cancers are estrogen receptor α (ER) positive. ER-positive breast cancers are welldifferentiated and have a better outcome compared to other subtypes [1, 2] . In this respect, tamoxifen is a frequently used and effective drug for patients diagnosed with ER-positive disease. However, half of ER-positive patients who receive tamoxifen as first-line therapy for recurrent disease do not respond to the treatment due to intrinsic resistance, while the other half initially responding patients become resistant during treatment [3] . To better understand the mechanism involved in this intrinsic and acquired resistance and to be able to predict which patients are likely to respond to tamoxifen, the identification of novel markers predicting the efficacy of tamoxifen treatment is highly needed.
GATA3 belongs to a family of zinc-finger transcription factors and is involved in embryogenesis and the differentiation of a variety of human tissues, including kidney, skin, breast and the central nervous system [4] [5] [6] [7] [8] . Both in the normal mammary gland and breast cancer tissue, GATA3 and ER expression are highly correlated [6, 9] . In fact, GATA3 is expressed in the normal luminal epithelial cells where it maintains luminal cell differentiation [7] , whereas in breast cancer GATA3 is highly expressed in the luminal subtype, regulating differentiation and suppressing dissemination [7, 10, 11] . Furthermore, GATA3 is an integral component of the ER pathway as it regulates the pioneer factor FOXA1 and mediates ER binding by shaping enhancer accessibility [7, 12] . Consequently, a large overlap exists between coexpressed genes for ER and GATA3, including many well-known ER pathway genes [13] . Since the expression of ER has important implications for both prognosis and treatment of breast cancers, several studies have assessed the association of GATA3 with clinical outcome. High GATA3 protein expression was shown to be associated with a lower grade, smaller tumor size and increased ER and PR expression [14] [15] [16] [17] [18] . In line with these findings, some, but not all, studies have shown that both GATA3 mRNA and GATA3 protein expression are independent prognostic markers, where high levels of GATA3 associate with a longer disease-free and overall survival in breast cancer patients [14, 15, [18] [19] [20] [21] . Furthermore, in a small study of Parikh et al. high levels of GATA3 protein were predictive of hormone responsiveness in ER-positive breast cancer patients [22] . In the neoadjuvant setting both GATA3 mRNA and GATA3 protein expression were shown to be predictive of a favorable response to chemotherapy [17, 23] .
The human GATA3 gene is a highly conserved gene located at 10p14-15 and consists of six exons which encode a protein of 444 residues [24] . Germline mutations of GATA3 cause a rare and complex disease of hypoparathyroidism, sensorineural deafness and renal insufficiency (HDR syndrome) [25] . In breast cancer, GATA3 is one of the most frequently mutated genes [26] [27] [28] [29] and sporadic heterozygous GATA3 mutations have been identified in approximately 5-20% of ER-positive breast cancers [30] . These mutations mostly cluster in the vicinity of the second zinc finger of GATA3 [31] and are virtually absent among ER-negative breast cancers. Interestingly, GATA3 mutations were correlated with improved diseasefree and overall survival in breast cancer patients overall, but also in ER-positive breast cancer patients who received adjuvant endocrine therapy [32] . Furthermore, mutations in GATA3 were also shown to be correlated with response to neoadjuvant aromatase inhibition treatment [33] . This suggests that GATA3 mutation may be a determinant of the response to hormonal treatment.
To investigate this hypothesis, we analyzed exons 5 and 6 of the GATA3 gene for mutations in 235 ER-positive primary breast cancers and evaluated the association of the identified mutations with the ORR and PFS of first-line tamoxifen therapy given for recurrent disease, as well as with GATA3 mRNA expression levels.
Materials and methods

Study population
This retrospective study included 235 female breast cancer patients ( Fig. 1) and was approved by the Medical Ethical Committee of the Erasmus Medical Center Rotterdam, the Netherlands (MEC 02.953). In this study we adhered to the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl) and results are reported in accordance with the REMARK criteria on clinical reporting [34] . All patients were diagnosed between 1979 and 1996 with measurable breast cancer disease, underwent primary surgery and were treated with tamoxifen as first-line treatment that was given for recurrent disease. Primary tumors were ER-positive and a minimum of 100 mg of fresh frozen tissue was required for downstream DNA and RNA extraction [35] . ER and/or PR positivity was defined by ≥10 fmol/mg cytosolic protein [36, 37] and ERBB2 overexpression was defined by a reverse transcriptase quantitative PCR (RT-qPCR) expression level ≥18 [38] . The patients did not receive neo-adjuvant therapy or adjuvant hormonal treatment, did not experience previous other cancers and did not show subjective or objective toxicity [35] . There were 296 patients that fulfilled these criteria and from whom detailed clinical follow up and primary tumor DNA was available. However, 60 patients were excluded as the percentage of tumor cell nuclei was below 50%, precluding reliable mutation analysis. Furthermore, mutation analysis failed in 1 patient, totaling to n = 235 included in the present study. From these, 84 patients underwent breast-conserving lumpectomy and 151 underwent modified mastectomy. In addition, 17 patients received adjuvant anthracycline-containing chemotherapy and 14 received adjuvant chemotherapy without anthracyclines. There were 209 M0 patients and 26 M1 patients. The median age at the time of the primary surgery was 57 years, while the median age at the start of first-line treatment was 61 years. Criteria for follow up and response to tamoxifen therapy were defined by standard International Union Against Cancer criteria of tumor response [39] . Complete and partial remission (together objective response) was observed in 4 and 34 patients, respectively, whereas 52 patients had progressive disease. From the patients with stable disease, 132 had no change for longer than 6 months, whereas 13 patients had no change for ≤6 months. According to the advice of the European Organization for Research and Treatment of Cancer [40] , we defined overall response as complete and partial remission including stable disease >6 months. As a result, 170 patients were classified as responders to tamoxifen and 65 patients showed no response to tamoxifen. The median follow up of patients after the start of tamoxifen therapy was 49 months (range: 4-208 months). At the end of the follow up, 224 patients had developed tumor progression and 196 patients had died.
From 148 of the 235 patients we had total RNA of sufficient quality from the primary tumor available (i.e. at an input of 10 ng total RNA amplifiable for 3 reference genes within 25 cycles) in order to perform GATA3 mRNA expression analysis by RT-qPCR. The clinicopathological variables of the patients are shown in Table 1 .
Mutation analysis
Genomic DNA previously extracted from the fresh frozen primary breast tumor of 235 patients [41] and quantified by Picogreen was used at an input of 20 ng to amplify GATA3 exon 5 and 6 sequences. Subsequently, PCR amplicons were subjected to Sanger sequencing analysis on an ABI3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA). All mutations were confirmed by Sanger sequencing using an independently amplified template. For the splice acceptor site mutations we performed an exonic reverse transcriptase PCR (RT-PCR) on a RNA template instead of PCR on a DNA template. We reported GATA3 mutations and predicted protein changes according the HGVS recommendations for the description of sequence variants [42] . PCR and sequencing primer sequences are available in Table S1A and B.
Expression analysis
Total RNA was extracted and cDNA was synthesized previously from the fresh frozen primary breast tumor of 148 patients as described before [35] . qPCR for GATA3 was performed in a Mx3000P™ Real-Time PCR System (Agilent, Amsterdam, the Netherlands) using SensiFast Probe Lo-Rox master mix (GC Biotech, Alphen aan den Rijn, the Netherlands) and a Taqman Gene expression Assay kit from Applied Biosystems (Hs00231122_m1; spanning exons 2 to 3; Nieuwerkerk aan den IJssel, the Netherlands) with 40 rounds of amplification as recommended by the manufacturer. In addition to a negative control (i.e. genomic DNA), we also included a standard curve of a serially diluted cDNA sample consisting of pooled breast cancer cDNA samples in each PCR plate. The latter was done to ensure that the PCR efficiency between plates was comparable and to normalize the data obtained from different plates and experiments. GATA3 mRNA expression levels for the samples were determined relative to the average Cq value of our reference gene set consisting of hydroxymethylbilane synthase (HMBS), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and TATA-box binding protein (TBP), and quantified as follows: GATA3 expression = 2 Cq reference gene set − Cq GATA3 gene [35] . PCR primer sequences for the ref-
erence genes are available in Table S1C .
Statistical analyses
A χ 2 or a Fisher's exact test (when the expected frequency ≤5 in any of the groups) was used to evaluate the relation between GATA3 mutation status and the clinicopathological variables. The relation between GATA3 mRNA expression levels and the clinicopathological variables was evaluated using either the two-sample Wilcoxon rank-sum test (for 2 categories) or the Kruskal-Wallis equality-of-populations rank test (for 3 categories). The association with tamoxifen response was analyzed with a logistic regression model to calculate odds ratios (ORs) and their 95% confidence intervals (95% CIs). PFS analysis was performed by the Kaplan-Meier method for visualization purposes and differences between survival curves were calculated by the Peto & Peto modification of the Gehan-Wilcoxon test (which puts more weight on the earlier events) for GATA3 mutation status and the log-rank test for GATA3 gene Fig. 1 . Study design and patient subsets analyzed for GATA3 mutation status and GATA3 mRNA expression. The "All patients (N = 296)" box represents all hormonenaive patients diagnosed with recurrent breast cancer between 1979 and 1996 and were treated with first-line tamoxifen (details provided in the Materials and methods section). For the GATA3 mutation analysis 60 patients were excluded whose tumor cell nuclei percentage was below 50% and mutation analysis failed in one patient. From these 235 patients, total RNA of sufficient quality was available for 148 patients for GATA3 RT-qPCR analysis. Clinical endpoints were the overall response rate (ORR) and progression-free survival (PFS).
expression. Univariate and multivariate Cox proportional hazards regression models were applied to calculate the hazards ratios (HRs) and 95% CIs in the analysis for the PFS. Log2-transformed expression values for GATA3 mRNA, ER and PR protein and ERBB2 mRNA were used in logistic and Cox regression analyses. All P-values were two-sided and P-values smaller than 0.05 were considered to be statistically significant. Analyses were performed using R, version 3.2.3.
Results
Since at the start of this study all of the GATA3 mutations reported so far clustered in exons 5 and 6 of the GATA3 gene, which encode the highly conserved second zinc finger required for DNA binding, we limited sequence analysis to these two exons. In total, we identified at least one GATA3 sequence variant in 54 out of the 235 primary tumors of patients with ER-positive recurrent breast cancer. A silent mutation in exon 5 (rs11567941; c.1257G>A; p.T122T; minor allele frequency (MAF) = 0.02) was identified in 24 tumors; however, we did not consider this mutation to be pathogenic. Furthermore, we identified a frameshift insertion in 22 tumors, a frameshift deletion in five tumors and a splice site deletion in six tumors (Table 2 ). These mutations predicted prematurely truncated proteins in 14 tumors and proteins with a longer C-terminal tail in 19 tumors. In total, we identified 33 GATA3 mutations that we considered to be pathogenic in 33 (14.0%) out of 235 ERpositive primary breast tumors.
Next, we evaluated the association between GATA3 mutation status and the clinicopathological variables (Table 1) , the ORR (Table S2 ) and the length of PFS after start of tamoxifen treatment (Table S2 and Fig. 2A) . We found no relation between GATA3 mutation and any of the clinicopathological variables (Table 1) . Table S2 ) or with the length of PFS in Kaplan-Meier (P = 0.80; Fig. 2A ) and Cox regression analysis (HR = 0.95, 95% CI = 0.65-1.40, P = 0.81; Table S2 ). Also subsetting by the type of mutation (i.e. mutations predicted to truncate versus elongate the protein) did not yield any significant differences. Although the number of patients was small, survival curves appeared very similar. However, logistic regression analysis did show that the traditional predictive factor diseasefree interval was associated with the efficacy of tamoxifen therapy (Table S2) . Similarly, the traditional predictive factors dominant site of relapse, disease-free interval and the level of PR protein expression were found to be associated with PFS (Table S2 ). These results implied that GATA3 mutation status is not a significant predictor for the outcome of tamoxifen therapy in patients with recurrent disease. Out of the 235 tumors for which we performed GATA3 mutation analysis, we were able to perform GATA3 mRNA expression analysis by RT-qPCR for 148 tumors. In 25 out of these 148 tumors we identified a GATA3 mutation and 123 tumors were wild-type. Interestingly, GATA3 expression levels were higher among mutant GATA3 tumors (i.e. irrespective of the predicted effect of the mutation) than wild-type GATA3 tumors (P = 0.0019). Eighteen tumors (72.0%) with GATA3 mutations had high GATA3 expression levels (i.e. above the median) while only seven tumors (28.0%) with GATA3 mutations had low GATA3 expression levels (i.e. below the median). However, out of the 76 GATA3 high expressing tumors, only 18 (23.7%) had a mutation in the GATA3 gene. Because the high levels of GATA3 mRNA were only partially explained by a mutation in GATA3 itself, we hypothesized that GATA3 expression instead of mutation might be associated with the outcome of tamoxifen treatment.
To evaluate this, we made use of the GATA3 mRNA expression data for all 148 primary breast tumors from recurrent breast cancer patients that we had generated by RT-qPCR. We found that GATA3 expression was associated with dominant site of relapse and PR protein status, but not with menopausal status, tumor grade, tumor size, nodal status, disease-free interval or ERBB2 mRNA status (Table 1 ). In univariate logistic regression analysis, we found no association of GATA3 expression level with the ORR for tamoxifen (64.9% versus 66.2%; OR = 1.12, 95% CI = 0.90-1.41, P = 0.31; Table 3 ). Additionally, menopausal status, dominant site of relapse and ER protein, PR protein and ERBB2 mRNA expression levels were also not associated with the ORR for tamoxifen, in contrast to diseasefree interval (Table 3) . GATA3 expression was, however, associated with the length of PFS, as it was prolonged for patients with tumors with high GATA3 mRNA levels compared to those with low levels (P = 0.033; Fig. 2B ). Concordantly, in univariate Cox regression analysis, high GATA3 expression levels were significantly associated with Fig. 2 . Kaplan-Meier analysis of progression-free survival (A) according to GATA3 mutation status for 235 ER-positive breast cancer patients who received first-line tamoxifen therapy for recurrent disease. The difference between the survival curves was calculated using the Peto & Peto modification of the Gehan-Wilcoxon test. (B) Dichotomized at median GATA3 expression level for 148 ER-positive breast cancer patients who received first-line tamoxifen therapy for recurrent disease. The difference between the survival curves was calculated using the log-rank test.
Table 3
Univariate logistic regression analysis of the overall response rate in 148 ERpositive breast cancer patients treated with first-line tamoxifen for recurrent disease. a prolonged PFS (HR = 0.87, 95% CI = 0.78-0.98, P = 0.017; Table 4 ). Besides GATA3 expression levels, also disease-free interval, but not menopausal status, dominant site of relapse and ER protein, PR protein and ERBB2 mRNA expression levels, were associated with the length of PFS (Table 4) . In multivariate analysis, by including GATA3 expression in a model with all the traditional predictive factors, GATA3 expression levels were significantly associated with a prolonged PFS (HR = 0.85, 95% CI = 0.75-0.96, P = 0.0079; Table 4 ). These results imply that GATA3 mRNA expression, rather than genetic aberration of the gene alone, is an independent predictor for the length of PFS in hormone-naive ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Discussion
GATA3 is one of the most frequently mutated genes in breast cancer [26] [27] [28] [29] and mutations in GATA3 are associated with improved survival [32] . Because GATA3 mutations are also associated with both a favorable outcome among ER-positive patients who received adjuvant endocrine treatment as well as response to neoadjuvant aromatase inhibitors [32, 33] , we here evaluated whether GATA3 mutations measured in the primary tumor (i.e. all ER positive) can determine the outcome of patients treated with first-line tamoxifen for recurrent disease. However, GATA3 mutations were not significantly associated with either the ORR or with PFS in 235 ER-positive breast cancer patients who received tamoxifen as a first-line therapy for recurrent disease (Table S2 and Fig. 2A ). Even though GATA3 mutations were associated with increased levels of GATA3 expression, only GATA3 expression was found to be an independent predictor for prolonged PFS (Table 4) . Our results suggest that not GATA3 mutation, but rather GATA3 expression predicts the length of PFS. This result will need to be validated in an independent patient population.
Jiang et al. have previously shown that GATA3 mutations were associated with improved survival in both the TCGA cohort as well as the Chinese FUSCC cohort [32] . In the TCGA cohort, however, this prognostic effect was limited to ER-positive breast cancer cases (overall survival P = 0.041) in contrast to all cases in the FUSCC cohort (overall survival P = 0.033). Furthermore, in the FUSCC cohort, GATA3 mutations were also associated with longer disease-free survival in ER-positive patients who received adjuvant endocrine treatment (P = 0.046), which may suggest a role for GATA3 mutation in the efficacy of endocrine therapy. However, our results do not show that GATA3 mutations are associated with the outcome of tamoxifen treatment in 235 ER-positive patients who were treated with first-line tamoxifen for recurrent disease (Table S2 and Fig. 2A ). This suggests that the improved disease-free survival of patients with GATA3 mutated tumors in the FUSCC cohort can be attributed to a pure prognostic association of GATA3 mutation rather than its role as a predictive factor for tamoxifen efficacy. Noteworthy, however, is that GATA3 mutations in the neoadjuvant setting were a predictive marker of favorable outcome of aromatase inhibitor treatment [33] . In that study, 77 ER-positive breast cancer samples were sequenced and GATA3 mutations were more frequently present in aromatase inhibitor sensitive tumors (P = 0.01). The apparent discrepancy between our study and the study of Ellis et al. might be attributable to a difference in the mechanism of action between aromatase inhibitors and tamoxifen or, probably more likely, due to the difference in primary versus recurrent disease receiving endocrine treatment and the used endpoints.
At the gene expression level, high GATA3 has consistently and independently of other clinicopathological predictors been linked to a better outcome [14, 19 ], but at the protein level the prognostic effect of GATA3 remains controversial [15, 18, 20, 21] . Higher sensitivity and/or accuracy of gene expression compared with protein expression measurement methods could very well explain poor consistency at the protein level. Interestingly, in a small study including only 28 patients and examining the expression of GATA3 by immunohistochemistry, Parikh et al. found that GATA3 expression predicted hormone responsiveness in breast cancer as six of 14 (43%) cancers were GATA3 negative in the hormone-unresponsive group and 0 of 14 (0%) cancers were GATA3 negative in the hormoneresponsive group (P = 0.031) [22] . These results are in line with the current study, where we analyzed GATA3 gene expression levels in 148 ER-positive recurrent breast cancer patients who were treated with first-line tamoxifen and found that high levels of GATA3 were associated with a prolonged PFS (Fig. 2B) . Moreover, in multivariate analysis, GATA3 expression was an independent predictor of progression-free survival (Table 4 ). The predictive effect of GATA3 at the protein level, however, requires independent examination.
In the current study, we also observed that breast cancers with a GATA3 mutation had significantly higher GATA3 expression levels, although only GATA3 expression appeared to be associated with prolonged PFS. Importantly, from the 76 breast cancers with high GATA3 expression levels, 18 (23.7%) had a GATA3 mutation. Thus, a significant fraction (n = 58, 76.3%) of the GATA3 high breast cancers does not have a GATA3 mutation. In order to be certain that we did not miss any mutations located outside exons 5 and 6, we additionally sequenced the other coding exons (i.e. exons 2-4) of the GATA3 gene in these 58 breast cancers, but did not find any additional mutations. This not only confirms that the vast majority of GATA3 mutations are actually located in exons 5 and 6, but this also suggests that there are other mechanisms besides GATA3 mutation that may be responsible for the high GATA3 expression in ER-positive breast cancers with a wild-type GATA3 gene. As the GATA3 transcription factor reshapes gene loci by recruiting chromatin remodeling complexes, mutations of these proteins present in these complexes or other upstream pathway members could very well be involved in these mechanisms. For example, GATA3 expression was recently also reported to be increased by Wnt/β-catenin pathway activation in adipocytes [43] . Identification of these players may lead to a better understanding of the mechanisms of resistance to tamoxifen treatment by transcriptional regulation through GATA3, the crucial transcription factor regulating luminal differentiation in the mammary gland.
In conclusion, not GATA3 mutation, but GATA3 gene expression is associated with prolonged PFS in ER-positive breast cancer patients who received first-line tamoxifen treatment for recurrent disease. In addition, GATA3 mutation leads to an increased GATA3 mRNA expression, but besides genetic aberration of GATA3, other mechanisms are in place to explain the increased GATA3 levels in GATA3 wild-type tumors with high GATA3 mRNA.
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